JBNI, Herbal Medicine, Genomics, and Biotechnology

Herbal medicines are considered health food in many Western nations. This perception is due to the slow action and low efficacy of herbal medicine.

JBNI scientists have formulated fast acting, safe, all-natural, food-grade, herbal remedies that are as effective as commercial pharmaceutical drugs. JBNI scientists have been developing naturaceuticals for decades.

In 1974, the scientists of JBNI (aka DHI) succeeded in developing all natural NSAID's (Non-Steroidal Anti-Inflammatory Drugs). While developing non-anaphylactic NSAIDs, they additionally succeeded in combining the strong anti-inflammatory function with anti-bacterial, anti-viral, anti-fungal, and anti-amoebic qualities by focusing on boosting the human immune function. As a result, the natural Formula 15.1 became the first anti-biotic which also eliminates fungal growth and is a powerful anti-inflammatory.

In 1978, JBNI (then OMR) scientists further succeeded in formulating over 50 natural internal and external remedies. These formulas have proven themselves to be as gentle as food while as effective as brand name pharmaceuticals.

In 1989, JBNI (then JJHC) succeeded in further improving Formula 15.1 by strengthening its anti-inflammatory action and pain killing capability by 400%. This improvement necessitated a new designation as Formula 15.3.

In 1991, JBNI (then JJI) scientists collaborated with TSRA (Triple S Research Associates) further improving the overall safety and efficacy. All of the oral formulas were raised to a new level of safety, beyond any government or public standard. Results achieved included yielding zero side effects with a single dose at 1/500 -1/100 of body weight. Many formulas were also tested against metastatic breast cancer (closely related to lung cancer), colorectal cancer, and skin cancer.

While JBNI and TSRA scientists were striving to set new industrial standards, they discovered that the FDA did not yet set any limitations on heavy metals in food products. FDA scientists developed new standards on heavy metal, herbicide, and pesticide content in the health food products due to data from TSRA and JBNI scientists.

In 1993, JBNI (aka JJI) began distributing nutritional health supplements exclusively to licensed physicians in the USA, including MDs, DOs, LAcs and DCs. This decision was implemented as part of a long-term clinical observation strategy.

Since 2001, JBNI (aka JJI) scientists intensified their research in the fields of genomics, genetics, DNA, proteomics and biomarkers. Together with IDD, CTRC, Beckman, Cyphergen, Luminex, Millipore, and Panomics, JBNI scientists succeeded in identifying biomarkers for forecasting many types of cancer decades before they strike. JBNI scientists, together with IDD, CTRC, and CPC, have been leading their peers in cancer prevention studies ever since. Abstracts documenting their
collaboration are featured annually in AACR, NIH, NCI, and EORTC conventions.

In 2004, JBNI's Azmazin received an IND (Investigational New Drug) number from the FDA as an asthma drug. It is expected to soon become the historic first oral and natural drug approved by the FDA. JBNI plans to further apply for drug approval for each of their products once Azmazin's approval process is finalized.

In 2007, JBNI, after three decades of carefully observed and private physician-only distribution, JBNI made select products available to the public. These products are sold as nutritional supplements with no claims. That same year, JBNI made these formulas available to the public online.

A Proteomics Victory Over Cancer

04/14/07: Latest RCC Abstract

06/14/06: Our latest abstract

July 2005 our research in the battle against cancer won recognition in the scientific and pharmaceutical community to the extent that we have been presented on the cover of the July-August issue of " Cancer Genomics & Proteomics" , a journal published by the International Institute of Anticancer Research.

Novel natural products LP-01 and LP-02 developed by JBNI, were presented in cooperation with CTRC The Institute for Drug Development, San Antonio, TX at AACR-NCI-EORTC 2004: September 28-October 1, Geneva, Switzerland The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications was held in Geneva, Switzerland this past September. Our abstract on Serum Proteomic Biomarkers of a Natural Product in a Prospective Randomized Placebo-Controlled Clinical Trial in patients at risk for lung cancer was presented to the acclaim of the attendees.

In November of 2003, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery Biology, and Clinical Applications held in Boston, Massachusetts, an abstract entitled "Serum Biomarkers of Natural Product Therapy in Human Lung Cancer Xenograft Models" was presented, demonstrating the efficacy of our novel entities (LP-01 and LP-02) in high-risk lung cancer patients.

read our report on Novel serum biomarkers for renal cell carcinoma